Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines
Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines
复制标题
DOI：
10.1111/j.0902-4441.2005.t01-1-ejh2437.x
复制
发表时间：
2006-03-01
影响因子：
3.1
通讯作者：
Park, G
中科院分区：
文献类型：
--
作者：
Min, CK;Lee, S;Park, G
蛋白酶体抑制剂硼替佐米（bortezomib）即使在先前多次治疗难治的骨髓瘤细胞中也具有抗骨髓瘤活性。硼替佐米可阻断核因子 kappa B (NF kappa B) 介导的促炎细胞因子的产生。我们报告了一名骨髓瘤患者在硼替佐米治疗后出现皮肤白细胞碎裂性血管炎（LV）。 LV 患者的血清 IL-6、TNF-α 和 C 反应蛋白 (CRP) 水平显着升高。硼替佐米给药可能会增强促炎细胞因子的释放，这可能在硼替佐米诱导的皮肤左心室中发挥作用。
The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-kappa B (NF kappa B)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-alpha, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.